Early prognostic performance of miR155-5p monitoring for the risk of rejection : Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients
Quintairos, Luis (Hospital Clínic i Provincial de Barcelona)
Colom, Helena (Universitat de Barcelona. Departament de Farmacologia, Toxicologia i Química Terapèutica)
Millan, Olga (Instituto de Salud Carlos III)
Fortuna, Virginia (Hospital Clínic i Provincial de Barcelona)
Espinosa, Cristina (Hospital Clínic i Provincial de Barcelona)
Guirado, Luis (Institut d'Investigació Biomèdica Sant Pau)
Budde, K (Charité - Universitätsmedizin Berlin)
Sommerer, Claudia (Heidelberg University Hospital (Alemanya))
Lizana, Ana (Hospital Clínic i Provincial de Barcelona)
Lopez-Pua, Yolanda (Hospital Clínic i Provincial de Barcelona)
Brunet, Mercè (Instituto de Salud Carlos III)

Data:	2021
Resum:	Previous results from our group and others have shown that urinary pellet expression of miR155-5p and urinary CXCL-10 production could play a key role in the prognosis and diagnosis of acute rejection (AR) in kidney transplantation patients. Here, a logistic regression model was developed using NONMEM to quantify the relationships of miR155-5p urinary expression, CXCL-10 urinary concentration and tacrolimus and mycophenolic acid (MPA) exposure with the probability of AR in adult kidney transplant patients during the early posttransplant period. Owing to the contribution of therapeutic drug monitoring to achieving target exposure, neither tacrolimus nor MPA cumulative exposure was identified as a predictor of AR in the studied population. Even though CXCL-10 urinary concentration showed a trend, its effect on AR was not significant. In contrast, urinary miR155-5p expression was prognostic of clinical outcome. Monitoring miR155-5p urinary pellet expression together with immunosuppressive drug exposure could be very useful during routine clinical practice to identify patients with a potential high risk of rejection at the early stages of the post-transplant period. This early risk assessment would allow for the optimization of treatment and improved prevention of AR.
Nota:	Altres ajuts: TEVA Pharmaceuticals (EudraCT number: 2013-001817-33); Mutua Madrileña (AP153362014).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adult ; Female ; Gene Expression Regulation ; Graft Rejection ; Humans ; Kidney Transplantation ; Logistic Models ; Male ; MicroRNAs ; Middle Aged ; Models, Biological ; Mycophenolic Acid ; Prognosis ; Risk ; Tacrolimus
Publicat a:	PloS one, Vol. 16 Núm. 1 January (january 2021) , p. e0245880, ISSN 1932-6203

DOI: 10.1371/journal.pone.0245880
PMID: 33481955

20 p, 1.3 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats